menu
    • menu

    Company profile for CStone Pharmaceuticals

    NEW Drugs in Dev: 14
    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    European CDMO and Gx manufacturer with 75 years of experience in delivering premium APIs to pharmaceutical partners worldwide.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-01-12

    Virtual Booth

    Contact Supplier

    Evonik Health Care is the innovation hub for leading life science companies

    Virtual Booth

    Contact Supplier

    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-2026-02-09

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    CStone Pharmaceuticals is a biopharmaceutical company devoted to the development of a new generation of innovative drugs. With its broad immuno-oncology pipeline, CStone is pursuing a development strategy focusing on combination therapy. CStone has successfully built up an industry leading team with clinical development and translational medicine as its core competence. This enables CStone to accelerate drug approval timeline,...
    CStone Pharmaceuticals is a biopharmaceutical company devoted to the development of a new generation of innovative drugs. With its broad immuno-oncology pipeline, CStone is pursuing a development strategy focusing on combination therapy. CStone has successfully built up an industry leading team with clinical development and translational medicine as its core competence. This enables CStone to accelerate drug approval timeline, while at the same time, apply global standard practices to ensure clinical trial quality.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    CStone PharmaceuticalsChina Flag
    Country
    Country
    China
    Address
    Address
    C1, Bio-Nano Park, No. 218, Xinghu Street, Suzhou Industrial Park- 215123
    Telephone
    Telephone
    +86-(0)512-8718-6550
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.cstonepharma.com/
    Linkedin
    Linkedin
    https://in.linkedin.com/company/cstone
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    ASPEN

    ASPEN

    Not Confirmed

    envelop Contact Supplier

    ASPEN

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    CStone Advances Trispecific Antibody CS2009 To Phase II Trial
    CStone Advances Trispecific Antibody CS2009 To Phase II Trial

    16 Feb 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/cstone-announces-fda-clearance-of-ind-application-for-its-novel-trispecific-antibody-cs2009-pd-1vegfctla-4-to-advance-into-phase-ii-clinical-trial-302688307.html

    PR NEWSWIRE
    16 Feb 2026
    Share Share
    ACAAI 2025: CS2015 Bispecific Antibody Debuts Globally
    ACAAI 2025: CS2015 Bispecific Antibody Debuts Globally

    06 Nov 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/acaai-2025--cs2015-ox40ltslp-bispecific-antibody-makes-international-debut-302606851.html

    PR NEWSWIRE
    06 Nov 2025
    Share Share
    Cstone Reveals Phase I Results For CS2009 Trispecific Antibody
    Cstone Reveals Phase I Results For CS2009 Trispecific Antibody

    20 Oct 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/esmo-2025-cstone-discloses-phase-i-data-for-cs2009-pd-1vegfctla-4-trispecific-antibody-302588362.html

    PR NEWSWIRE
    20 Oct 2025
    Share Share
    CStone Presents Preclinical Results of CS2011, CS5007, CS5005
    CStone Presents Preclinical Results of CS2011, CS5007, CS5005

    06 May 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/cstone-presents-preclinical-results-of-cs2011-egfrher3-bispecific-antibody-cs5007-egfrher3-bispecific-adc-cs5005-sstr2-adc-and-cs5006-itgb4-adc-at-2025-aacr-302447053.html

    PR NEWSWIRE
    06 May 2025
    Share Share
    CStone Reveals Preclinical Findings of CS2009 at 2025 AACR
    CStone Reveals Preclinical Findings of CS2009 at 2025 AACR

    05 May 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/cstone-presents-the-latest-preclinical-findings-of-cs2009-pd-1vegfctla-4-trispecific-antibody-at-2025-aacr-302446074.html

    PR NEWSWIRE
    05 May 2025
    Share Share
    CStone Pharmaceuticals Announces 2024 Results and Progress
    CStone Pharmaceuticals Announces 2024 Results and Progress

    27 Mar 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/cstone-pharmaceuticals-announces-2024-annual-results-and-recent-business-progress-302413130.html

    PR NEWSWIRE
    27 Mar 2025
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search